Recipharm acquires GenIbet to bolster Biologics offering
Global contract development and manufacturing organisation (CDMO), Recipharm, has today announced the acquisition of GenIbet, a Portuguese CDMO, specialising in the manufacture of biological clinical trial material and novel modalities such as viral vectors, RNA and microbiome. The acquisition forms part of Recipharm’s strategy to grow in the Biologics market, with a particular focus on drug substance manufacturing of novel ATMPs. GenIbet currently works with customer projects in the preclinical and Phase 1 stages and has a track record of developing novel production processes.